172 results
Page 5 of 9
8-K
n2cr agd0vobchs37
29 Apr 20
Other Events
8:06am
8-K
EX-99.1
pxfaisrc1sa8emnzqn4
29 Apr 20
Other Events
8:06am
8-K
EX-99.1
88e5p7
28 Apr 20
Other Events
8:26am
8-K
EX-99.1
coutb0ns 2r60rm
27 Feb 20
Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update
7:39am
8-K
EX-99.1
cywvd obbnngupdqj6sc
18 Feb 20
Adaptimmune Announces Appointment of Gavin Wood as Chief Financial Officer
8:07am
8-K
EX-99.1
mw2t5mdav4zex
7 Feb 20
Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional American Depositary Shares
4:20pm
424B5
waqca6k
22 Jan 20
Prospectus supplement for primary offering
5:31pm
8-K
EX-1.1
rfac2dsf1sjld5bb76q
22 Jan 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
5:30pm
8-K
EX-99.2
5un v4bql8
22 Jan 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
5:30pm
8-K
EX-99.1
1m7bnwoeqtoc69b9
22 Jan 20
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
5:30pm
424B5
mdlrxmfcjggbbe wbv
21 Jan 20
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
cs3p0yvv2ij
14 Jan 20
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies
6:17am
8-K
EX-99.1
1jedz5qqoj93tazzfa
13 Jan 20
Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership
8:42am
8-K
EX-99.1
gtonyruylgp
13 Jan 20
Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
7:09am